<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03716921</url>
  </required_header>
  <id_info>
    <org_study_id>P170911J</org_study_id>
    <secondary_id>IDRCB</secondary_id>
    <nct_id>NCT03716921</nct_id>
  </id_info>
  <brief_title>Short 3-week Antibiotic Treatment Versus 6 Weeks in Adults With Septic Arthritis of Native Joint</brief_title>
  <acronym>SHASAR</acronym>
  <official_title>Short 3-week Antibiotic Treatment Versus 6 Weeks in Adults With Septic Arthritis of Native Joint: a Randomized, Open Label, Non-inferiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In France, the incidence of native joint infections is about 10 per 100 000 person-years,
      most commonly caused by S.aureus followed by b-haemolytic streptococci. French and
      international antibiotic guidelines, based on expert advice and retrospective studies,
      recommend intravenous antibiotics for two weeks, then oral for 4 weeks without evident link
      between intravenous, prolonged oral treatment and cure. Long term exposure to antibiotics
      increases bacterial resistance, a major problem of public health. Several studies show that
      serious infectious can be treated safely by a shorter treatment and with oral antibiotics.
      There is no randomized controlled trial to establish the duration of antibiotics in native
      joint infections. Moreover, no consensus prevails on the administration route and duration of
      antimicrobial therapy. Although most clinicians acknowledge the interest of oral antibiotics
      and shorter treatment duration, randomized controlled trials are necessary to evaluate this
      practice. The SHASAR project aims to evaluate whether a shorter antibiotic treatment (3 week
      treatment) is safe and not inferior to the conventional 6 week treatment in native joint
      infections. If successful, this would represent a major advance in terms of patients' quality
      of life; decreased rate of health-care-related infections and complications, bacterial
      resistance and cost.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is a nationwide, non inferiority, multicenter French randomized, open-label,
      controlled trial comparing two treatment durations, 3 versus 6 weeks, in septic arthritis of
      native joints. Patients who fulfill inclusion criteria will be randomized between day0 and
      day5. Day 0 is the time when effective intravenous antibiotic treatment is started. Effective
      treatment is defined by active antibiotics on the identified bacteria according to the
      susceptibility. The randomisation (1:1 ratio) will be stratified on early planned drainage.
      Follow-up will include 6 visits and will consist in clinical, biological, radiological,
      health quality of life (EQ-5D-3L score) and adverse events record. After collection,
      validation of data and population description, analysis will be conducted on the per-protocol
      population (patients receiving the planned duration of antibiotic +/-3days). This study will
      not be carried out blind for feasibility reasons. According to statistical considerations (by
      accounting for 5% of subjects lost to follow-up), the required sample size will be of 350
      patients overall.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 5, 2019</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cure at 16 weeks (4 months) after the beginning of the treatment</measure>
    <time_frame>16 weeks after Day 0</time_frame>
    <description>Cure is defined as absence of clinical signs of joint infection, absence of treatment failure, absence of relapse</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cure at 24 weeks</measure>
    <time_frame>24 weeks after Day 0</time_frame>
    <description>Cure is defined as absence of clinical signs of joint infection, absence of treatment failure, absence of relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment failure and relapse and relapse rates</measure>
    <time_frame>6,16,24 weeks after Day 0</time_frame>
    <description>% of relapse at 6,16,24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The patient's quality of life</measure>
    <time_frame>3,6,16,24 weeks after Day 0</time_frame>
    <description>assessed by a quality of life questionnaire on 3,6,16,24 weeks. The EQ-5D-3L descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results into a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The residual joint pain in the affected joint</measure>
    <time_frame>at 16 and 24 weeks after Day 0</time_frame>
    <description>The residual joint pain is measured by a numerical scale. 0 means &quot;no pain at all&quot; and 10 &quot;pain as bad as it could be&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital length of stay and total treatments costs</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
    <description>To compare cost-effectiveness and cost utility of 3-week vs 6-week antibiotic strategies for patients with arthritis of native joints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>joint mobility</measure>
    <time_frame>at 16 and 24 weeks after Day 0</time_frame>
    <description>joint mobility is assessed by &quot;good mobility, few mobility, no mobility&quot;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Septic Arthritis</condition>
  <arm_group>
    <arm_group_label>Short antibiotics treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive effective antibiotic treatment (IV and oral) for 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long antibiotics treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients will receive effective antibiotic treatment (IV and oral) for 6 weeks according to standard care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Short antibiotics treatment</intervention_name>
    <description>Patients randomized in this arm will pursue antibiotic administration until visit 3 weeks after D0</description>
    <arm_group_label>Short antibiotics treatment</arm_group_label>
    <other_name>3-week antibiotic treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Septic arthritis of native joint defined by: 1) clinical signs (hot and/or swollen
             and/or tender and painful joint (measured by a visual analogue scale)) and 2)
             microbiologically confirmed pyogenic arthritis (microorganism cultured in the synovial
             fluid joint or in the blood with complete bacterial susceptibility)

          -  Patients aged of 18 years or older

          -  Informed, written consent obtained from the patient

          -  Patient having the rights to French social insurance

        Exclusion Criteria:

          -  Prosthetic joints

          -  Septic arthritis in the past 12 months

          -  Osteomyelitis

          -  Soft tissues abscess

          -  Diabetic foot

          -  Septic choc

          -  Arthritis due to bacteria resistant to available oral antibiotics

          -  Arthritis due to the following microorganisms: Mycobacterium, fungi, Brucella,
             Borrelia, Neisseria gonorrhoeae, Neisseria meningitidis, Nocardia, Mycoplasma spp,
             Pseudomonas aeruginosa.

          -  Glomerular filtration rate &lt; 30ml/min/1,73m2

          -  Neutrophils &lt; 500/mm3

          -  Difficulties regarding compliance with oral antibiotics

          -  Contraindication to oral antibiotics necessary to treat joint infection

          -  Pregnancy or lactating woman

          -  Curator or guardianship

          -  Participation in other interventional research during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lélia ESCAUT, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HP Hôpital Bicêtre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lélia ESCAUT, Dr</last_name>
    <phone>01 45 21 74 26</phone>
    <phone_ext>+33</phone_ext>
    <email>lelia.escaut@aphp.Fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Avicenne - Service de Maladies Infectieuses</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier BOUCHAUD</last_name>
      <email>olivier.bouchaud@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne - Service de Rhumatologie</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie Christophe BOISSIER, Dr</last_name>
      <email>marie-christophe.boissier@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Ambroise Paré - Service de Rhumatologie</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <zip>92104</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maxime BREBAN, Dr</last_name>
      <email>maxime.breban@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHG Pontoise - Centre Hospitalier René Dubos - Service de Rhumatologie</name>
      <address>
        <city>Cergy-Pontoise</city>
        <zip>95303</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edouard PERTUISET, Dr</last_name>
      <email>edouard.pertuiset@ch-pontoise.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Antoine Béclère - Service de Maladies Infectieuses</name>
      <address>
        <city>Clamart</city>
        <zip>92140</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie ABGRALL, Pr</last_name>
      <email>sophie.abgrall@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor - Service de Maladies Infectieuses</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sébastien Gallien, Dr</last_name>
      <email>sebastien.gallien@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor - Service de Rhumatologie</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xavier CHEVALIER, Dr</last_name>
      <email>xavier.chevalier@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Raymond Poincaré - Service de Maladies Infectieuses</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aurélien DINH, Pr</last_name>
      <email>aurelien.dinh@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Bicêtre, Service de Maladies Infectieuses et Tropicales</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lélia ESCAUT, Dr</last_name>
      <phone>01 45 21 74 26</phone>
      <phone_ext>+33</phone_ext>
      <email>lelia.escaut@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre service de rhumatologie</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier MARIETTE, Pr</last_name>
      <email>xavier.mariette@aphp.Fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisière Service de Rhumatologie</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascal RICHETTE, Dr</last_name>
      <email>pascal.richette@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine - Service de Rhumatologie</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jérémie SELLAM, Dr</last_name>
      <email>jeremie.sellam@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié Salpetrière - Service de Maladies Infectieuses</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphane JAUREGUIBERRY, Dr</last_name>
      <email>stephane.jaureguiberry@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié Salpetrière - Service de Rhumatologie</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno FAUTREL, Dr</last_name>
      <email>bruno.fautrel@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin - Service de Maladies Infectieuses</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique SALMON, Pr</last_name>
      <email>dominique.salmon@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin - Service de Rhumatologie</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yannick ALLANORE, Pr</last_name>
      <email>yannick.allanore@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker - Service de Maladies Infectieuses</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fanny LANTERNIER, Dr</last_name>
      <email>fanny.lanternier@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat - Service de Maladies Infectieuses</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xavier LESCURE, Dr</last_name>
      <email>xavier.lescure@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat - Service de Rhumatologie</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe DIEUDE, Dr</last_name>
      <email>philippe.dieude@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon - Service de Maladies Infectieuses</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ludovic LASSEL, Dr</last_name>
      <email>ludovic.lassel@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>October 10, 2018</study_first_submitted>
  <study_first_submitted_qc>October 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2018</study_first_posted>
  <last_update_submitted>April 16, 2019</last_update_submitted>
  <last_update_submitted_qc>April 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Septic Arthritis of native joint</keyword>
  <keyword>short antibiotic treatment</keyword>
  <keyword>native joint</keyword>
  <keyword>septic arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Infectious</mesh_term>
    <mesh_term>Arthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

